Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04486781
Title A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Vasgene Therapeutics, Inc

transitional cell carcinoma


Pembrolizumab + sEphB4-HSA

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.